Indivior faces share loss as Supreme Court denies hold request
Indivior
1,514.00p
17:10 24/04/24
The US Supreme Court on Tuesday denied Indivior's request for it to put on pause a lower court's decision that opens the door for the launches of potential copycat versions of its biggest-selling drug.
FTSE 250
19,719.37
17:09 24/04/24
FTSE 350
4,419.71
17:09 24/04/24
FTSE All-Share
4,374.06
16:44 24/04/24
Pharmaceuticals & Biotechnology
21,897.50
17:09 24/04/24
Chief Justice John Roberts denied the request to stay the Court of Appeals of the Federal Circuit's ruling that will allow generic versions of Indivior's Suboxone Film to be launched by India's Dr Reddy’s Laboratories and US-based Alvogen Pine Brook.
Indivior had asked for the appeals court decision to be paused while it prepared to launch a Supreme Court appeal.
Last week, the appeals court decided to allow the two companies to sell their generic versions of Suboxone, which Dr Reddy's and Avlogen are both expected to do despite being "at risk" of pending court judgments that they are infringing on Indivior's patents.
Indivior warned that the result of launched of such copycat drugs could see it could lose 80% of market share “in a matter of months”.